Evivo is a once-daily serving of Bifidobacterium longum subspecies infantis specially formulated for use in the NICU. Research indicates that B. infantis may be both restorative and protective in infants.2 Administering Evivo with breast milk is clinically proven to allow B. infantis to grow and dominate the infant gut microbiome while also reducing relative populations of less desirable bacteria.3
Evivo helps protect the NICU baby’s gut microbiome through a variety of actions derived from its ability to consume HMOs. It is anti-inflammatory, decreases intestinal permeability, and increases the production of short-chain fatty acids, particularly lactate and acetate, which can be protective in infants.2,4,5
A meta-analysis review found that administration of probiotics to infants in the NICU is safe and effective, and can reduce incidence of NEC and mortality.6 The authors also found that probiotic administration leads to shorter time to full feeds and may reduce incidence of sepsis.6 In the four years since the meta-analysis review was completed, further clinical research has concluded that not all probiotics are created equal. It is critical for the hospital to understand the mechanism by which the probiotic is working in their infants.
Evivo™ (activated B. infantis EVC001, ActiBif®) is able to utilize all the HMOs in breast milk and is able to consume them in a unique and superior manner compared to other bacteria. Evivo is then able to convert HMOs into nutrients that nourish both the infant and the gut microbiome and suppress the growth of potentially harmful bacteria.
Evivo is intended for use in term infants consuming human milk. If you have any questions about the use of the product, please consult a physician.
Choose Evivo for your patients for an optimal start to a healthy life.